BattelinoT, DanneT, BergenstalRM, et al.Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care, 2019; 42(8):1593–1603.
2.
American Diabetes Association. Professional practice committee glycemic goals and hypoglycemia: Standards of Care in Diabetes – 2025. Diabetes Care, 2025; 48(Suppl 1):S128–S145.
3.
BeckRW, RiddlesworthTD, RuedyK, et al.DIAMOND Study Group. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA, 2017; 317(4):371–378.
4.
TamborlaneWV, BeckRW, BodeBW, et al.Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med, 2008; 359(14):1464–1476.
5.
LindM, PolonskyW, HirschIB, et al.Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: The GOLD randomized clinical trial. JAMA, 2017; 317(4):379–387.
6.
LaffelLM, KanapkaLG, BeckRW, et al.CGM Intervention in Teens and Young Adults with T1D (CITY) Study Group; CDE10. Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: A randomized clinical trial. JAMA, 2020; 323(23):2388–2396.
7.
PratleyRE, KanapkaLG, RickelsMR, et al.Wireless Innovation for Seniors With Diabetes Mellitus (WISDM) Study Group. Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: A randomized clinical trial. J Amer Med Assoc, 2020; 323(23):2397–2406.
8.
TeoE, HassanN, TamW, KohS. Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: A systematic review of randomised controlled trials and meta-analysis. Diabetologia, 2022; 65(4):604–619.
9.
CarlsonA, SherrJ, ShulmanD, et al.Safety and glycemic outcomes during the MiniMedTM advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2022; 24(3):178–189.
10.
BretonM, KanapkaLG, BeckRW, et al.iDCL Trial Research Group. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med, 2020; 383(9):836–845.
11.
BrownSA, KovatchevB, RaghinaruD, et al.iDCL Trial Research Group. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med, 2019; 381(18):1707–1717.
12.
BrownSA, ForlenzaGP, BodeBW, et al.Omnipod 5 Research Group. Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care, 2021; 44(7):1630–1640.
13.
ThabitH, TauschmannM, AllenJM, et al.Home use of an artificial beta cell in type 1 diabetes. N Engl J Med, 2015; 373(22):2129–2140.
14.
BenhamouP-Y, FrancS, ReznikY, et al.DIABELOOP WP7 Trial Investigators. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: A 12-week multicentre, open-label randomised controlled crossover trial. Lancet Digit Health, 2019; 1(1):E17–E25.
15.
RussellSJ, BeckRW, DamianoER, et al.Bionic Pancreas Research Group. Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. N Engl J Med, 2022; 387(13):1161–1172.
16.
ChoudharyP, ArrietaA, Van den HeuvelT, et al.Celebrating the data from 100,000 real-world users of the MiniMedTM 780G system in Europe, Middle East, and Africa collected over 3 years: From data to clinical evidence. Diabetes Technol Ther, 2024; 26(S3):32–37; doi: 10.1089/dia.2023.0433
17.
BretonMD, KovatchevBP. One year real-world use of the Control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther, 2021; 23(9):601–608.
18.
ForlenzaGP, DeSalvoDJ, AleppoG, et al.Real-world evidence of Omnipod® 5 automated insulin delivery system use in 69,902 people with type 1 diabetes. Diab Tech Ther, 2024; 26(8):514–525; doi: 10.1089/dia.2023.0578
19.
ForlenzaGP, DaiZ, NiuF, et al.Reducing diabetes burden in medtronic’s automated insulin delivery systems. Diabetes Technol Ther, 2024; 26(S3):7–16.
20.
AlwanH, WilinskaME, RuanY, et al.Real-world evidence analysis of a hybrid closed-loop system. J Diab Sci Technol, 2023:19322968231185348.
21.
BenhamouPY, AdenisA, LebbadH, et al.One-year real-world performance of the DBLG1 closed-loop system: Data from 3706 adult users with type 1 diabetes in Germany. Diabetes Obes Metab, 2023; 25(6):1607–1613.
22.
VigerskyR, McMahonC. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther, 2019; 21(2):81–85.
23.
BeckRW, BergenstalRM, ChengP, et al.Cheng P The relationship of time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol, 2019; 13(4):614–626.
24.
DCCT Research Group. Hypoglycemia in the diabetes control and complications trial. The diabetes control and complications trial research group. Diabetes, 1997; 46:271–286.
25.
BeckRW, BergenstalRM, RiddlesworthTD, et al.Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care, 2019; 42(3):400–405.
26.
CastanedaJ, ArrietaA, Van den HeuvelT, et al.Time in tight glucose range in type 1 diabetes: Predictive factors and achievable targets in real-world users of the MiniMed 780G system. Diabetes Care, 2024; 47(5):790–797.
27.
Foland-RossLC, TongG, MaurasN, et al.Diabetes Research in Children Network (DirecNet). Brain function differences in children with type 1 diabetes: A functional MRI study of working memory. Diabetes, 2020; 69(8):1770–1778.
28.
OmladičJS, OzimicAS, VovkA, et al.Acute hyperglycemia and spatial working memory in adolescents with type 1. Diabetes Care, 2020; 43(8):1941–1944.
29.
MaurasN, BuckinghamB, WhiteNH, et al.Diabetes Research in Children Network (DirecNet). Impact of type 1 diabetes in the developing brain in children: A longitudinal study. Diabetes Care, 2021; 44(4):983–992.
30.
GrunbergerG, SherrJ, AllendeM, et al.American association of clinical endocrinology clinical practice guideline: The use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract, 2021; 27(6):505–537.
31.
American Diabetes Association Professional Practice Committee. Technology of Standards of Care in Diabetes—2025. Diabetes, 2025; 48(Suppl. 1):S146–S166.
32.
GriffinTP, GallenG, HartnellS, et al.UK’s Association of British Clinical Diabetologist’s Diabetes Technology Network (ABCD-DTN): Best practice guide for hybrid closed-loop therapy. Diabetic Med, 2023; 40:315078.
33.
JanezA, BattelinoT, KlupaT, et al.Hybrid closed-loop systems for the treatment of type 1 diabetes: A collaborative, expert group position statement for clinical use in Central and Eastern Europe. Diabetes Ther, 2021; 12(12):3107–3135.
34.
PhillipM, NimriR, BergenstalRM, et al.Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. Endocr Rev, 2023; 44(2):254–280.
35.
BiesterT, BergetC, BoughtonC, et al.ISPAD Clinical practice consensus guidelines 2024: Diabetes technologies: Insulin delivery. Horm Res Paediatr, 2024:1–34.
NICE. Hybrid Closed Loop Systems for Managing Blood Glucose Levels in Type 1 Diabetes. Available from: www.nice.org.uk/guidance/ta943 [Last accessed: June, 2024].
38.
BoucseinA, ZhouY, MichaelsV, et al.Automated insulin delivery for young people with type 1 diabetes and elevated A1c. NEJM Evid, 2024; 3(10):EVIDoa2400185.
39.
MichaelsVR, BoucseinA, WatsonAS, et al.Glucose and psychosocial outcomes 12 months following transition from multiple daily injections to advanced hybrid closed loop in youth with type 1 diabetes and suboptimal glycemia. Diabetes Technol Ther, 2024; 26(1):40–48.
40.
MatejkoB, Juza AA, Kiec-WilkB, et al.Transitioning of people with T1D from multiple daily injections and self-monitoring of blood glucose directly to MiniMed 780G advanced hybrid closed loop system: A two-center, randomized, controlled study. Diabetes Care, 2022; 45(11):2628–2635.
41.
PetrovskiG, CampbellJ, PashaM, et al.Simplified meal announcement versus precise carbohydrate counting in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed loop system. Diabetes Care, 2023; 46(3):544–550.
42.
PetrovskiG, CampbellJ, PashaM, et al.Twelve-month follow-up from a randomized controlled trial of simplified meal announcement versus precise carbohydrate counting in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system. Diabetes Technol Ther, 2024; 26(S3):76–83.
43.
OdugbesanO, AddalaA, NelsonG, et al.Implicit racial-ethnic and insurance-mediated bias to recommending diabetes technology: Insights from T1D exchange multicenter pediatric and adult diabetes provider cohort. Diabetes Technol Ther, 2022; 24(9):619–627.
